Results 11 to 20 of about 12,862 (201)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir

Journal of Investigative Medicine High Impact Case Reports, 2015
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD, Nira Roopnarinesingh MD, Nazia Qazi MD, Eric S Nylen MD   +3 more
doaj   +2 more sources

Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK-Based Therapy. [PDF]

Health Sci Rep
ABSTRACT Background Hepatitis C virus (HCV) infection is one of the leading causes of liver‐related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV
Joukar F, Yeganeh S, Eslami N, Mansour-Ghanaei F.   +3 more
europepmc   +2 more sources

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BMC Gastroenterology, 2020
Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C   +14 more
doaj   +1 more source

Efficacy and Adverse Effects of Sofosbuvir-Based Therapies (Double and Triple Regimens) in Chronic HCV Patients [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2017
Background and study aim: Egypt has the highest prevalence of hepatitis C virus in the world and it is about14.7 %. Until 2012, the combination of pegylated interferon-α and ribavirin was the standard of care in CHC.
Amal Jouda, Hosam Dawod, Nahla Elgammal
doaj   +1 more source

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. [PDF]

, 2017
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with ...
Kwo, Paul Y., Agarwal, Kosh, Muir, Andrew J., Buti, Maria, Symonds, William T., Mo, Hongmei, Afdhal, Nezam, Jacobson, Ira M., Marcellin, Patrick, Romero-Gómez, Manuel, Pang, Philip S., Foster, Graham R., Mangia, Alessandra, Chojkier, Mario, Ding, Xiao, Yang, Jenny C., Zarski, Jean Pierre, Bräu, Norbert, Gitlin, Norman, Puoti, Massimo, Buggisch, Peter, Forns, Xavier, Subramanian, G.Mani, Zeuzem, Stefan, McHutchison, John G.   +24 more
core   +2 more sources

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Background and aim There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV).
Waleed Ismail, Amr Hanafy, Mohammed Abdelsattar   +2 more
doaj   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

Український Журнал Нефрології та Діалізу, 2020
Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to ...
M. Mostafi, M. Jabin, Z. Chowdhury, M.U. Khondoker, S.M. Ali, R. Tamanna, R. Rezwan, S.B. Alomgir   +7 more
doaj   +1 more source

Comparison of Interferon-Based and Interferon-Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus-Sustained Virological Response: A Multicenter Study. [PDF]

Cancer Med
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Itoh S, Iseda N, Yoshizumi T, Ide T, Noshiro H, Sakai H, Hisaka T, Nakashima M, Nagano H, Okabe H, Hayashi H, Miyoshi A, Kitahara K, Takami Y, Nanashima A, Kuroki T, Endo Y, Okamoto K, Kajiwara M, Sakoda M, Beppu T, Takatsuki M, Eguchi S.   +22 more
europepmc   +2 more sources

HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]

, 2013
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is
Dillon, John, Hellard, M, Grebely, J ; https://orcid.org/, Hellard, Margaret, Goldberg, David J., Martin, Natasha K, Goldberg, DJ, Vickerman, P, Dore, Gregory J, Goldberg, David, Hickman, M ; https://orcid.org/, Hickman, Matthew, Lima, Viviane D, Grebely, J, Hutchinson, SJ, Dillon, John F.; id_orcid, Foster, Graham R., Lima, Viviane, Hickman, M, Martin, Natasha, Hutchinson, Sharon J.; id_orcid, Lima, VD, Martin, NK, Dore, Gregory J., Foster, Graham, Lima, Viviane D., Dore, Gregory, Vickerman, Peter, Goldberg, David J, Dillon, John F, Grebely, Jason, Hutchinson, Sharon, Hutchinson, Sharon J., Foster, Graham R, Dillon, JF, Dore, GJ ; https://orcid.org/, Foster, GR, Dillon, John F., Dore, GJ, Hutchinson, Sharon J, Martin, Natasha K.   +40 more
core   +1 more source